MedTrace Logo

A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain

NCT01820715 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2013-08-13

No results posted yet for this study

Summary

A multi-centers, placebo-controlled, randomized, double-blinded, pilot clinical trial is designed to evaluate the safety of the DA-3030 injection and to explore the efficacy for Neuropathic pain.

Conditions

  • Diabetic Neuropathy

Interventions

DRUG

600㎍ of DA-3030 Injection

DRUG

Placebo

Sponsors & Collaborators

  • Dong-A Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yoo Heon Ahn, M.D., Ph.D. · Hanyang University

  • Bong Yeon Cha, M.D., Ph.D. · Seoul St. Mary's Hospital, The Catholic University of Korea

  • Kyung Soo Ko, M.D, Ph.D. · Inje University

  • Tae Sun Park, M.D., Ph.D. · Chonbuk National University Hospital

  • Young Soo Park, M.D.,Ph.D. · Hanyang University

  • Choon Hee Chung, M.D., Ph.D. · Wonju Christian Hospital

  • In Joo Kim, M.D., Ph.D. · Pusan National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2013-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01820715 on ClinicalTrials.gov